NovaBridge Biosciences (NASDAQ: NBP) was added to the Nasdaq Biotech Index effective December 19, 2025, placing the company among the largest U.S. biotech firms listed on Nasdaq. The index membership is based on market‑capitalization and liquidity criteria, and the addition signals that NovaBridge meets the benchmark’s standards for size and trading volume.
The inclusion is expected to enhance the company’s liquidity and visibility among institutional investors, as the Nasdaq Biotech Index is a widely followed benchmark for the biotechnology sector. Companies added to the index often experience increased trading activity and greater analyst coverage, which can improve market perception and attract new capital.
On January 2, 2026, Executive Chairman Fu Wei and Chief Executive Officer Sean Fu will ring the Nasdaq opening bell, marking NovaBridge’s transition from a China‑focused entity to a U.S.‑based global platform. The ceremony underscores the company’s strategic pivot and its hub‑and‑spoke model that accelerates development of its immuno‑oncology pipeline.
The transformation began with a name change from I‑Mab to NovaBridge in October 2025 and a relocation of headquarters to the United States. The company has streamlined its pipeline to focus on assets such as givastomig, VIS‑101, ragistomig, and uliledlimab, and has secured a substantial cash balance that extends its runway for continued R&D investment.
Financially, NovaBridge reported a net loss for the nine months ended September 30, 2025, but the company’s cash reserves remain robust, supporting its long‑term development strategy. The focus on pipeline progress over short‑term profitability is typical for early‑stage biotech firms seeking to build a portfolio of high‑potential assets.
Fu Wei said the bell‑ringing ceremony celebrates the company’s “successful transition to a global biotech platform” and signals confidence in unlocking shareholder value in 2026. Sean Fu added that inclusion in the index “underscores the strength of our strategic vision and pipeline” and enhances visibility as the company accelerates development of its assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.